For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis Announces Encouraging Results from Phase 1c Study of Topical Pan LOX Inhibitor in Established Skin Scars
- Well tolerated with good safety profile
- Marked change in scar composition with 30% reduction in collagen content
- First ever proof that LOX inhibition reduces skin collagen underpins expansion of Pharmaxis and Professor Fiona Wood collaboration into new skin fibrosis indications
- No overall improvements in scar appearance seen at 3 months points to need for longer study in established scars